ClinicalTrials.gg
RecruitingNCT07123779Updated Oct 30, 2026

HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

A Phase 1/2 interventional study of HS235 and Placebo in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction, sponsored by 35Pharma Inc., a GSK company. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by 35Pharma Inc., a GSK company · Phase 1/2, Interventional, and Treatment

Updated Oct 30, 2026Start date movedSponsor changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
75th of 286
126 · median 30
Started
2026
with 23 others
Phase 1/2
11 of 397
4 open now
Primary completion
2029-01
later than 62 of 85 live
Registered
365th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 75th largest by planned enrollment of the 286 interventional ones that give a count, is one of 24 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 62 of the 85 other live ones, and was the 365th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

Read the detailed description

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

03

Conditions studied

  • Pulmonary Hypertension
  • Heart Failure With Preserved Ejection Fraction
04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if they meet at least all the following criteria:

  1. Male or female, ≥ 18 years of age.
  2. [Sub-population A only - using a remote PAP sensor]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.

    Hemodynamic evidence of PH with:

    1. mPAP ≥ 25 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
    2. dPAP ≥ 15 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
    3. Hemodynamic evidence of pre-capillary PH based on presence of PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU obtained on most recent RHC obtained prior to screening.
  3. [Sub-population B only - without a remote PAP sensor]

    Hemodynamic evidence of Cpc-PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:

    1. PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU, and
    2. mPAP > 20 mmHg, and
    3. PAWP > 15 mmHg but \< 30 mmHg, and
    4. dPAP ≥ 15 mmHg.
  4. Established diagnosis of HFpEF with (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening..
  5. (NYHA) class II or III heart failure symptoms.
  6. Stable diuretic regimen during the screening period.
  7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening.
  8. 6-minute walking distance (6MWD) ≥ 100 m at screening.
  9. ≥ 25 to ≤ 50 kg/m2 and Body weight ≤140 kg.
  10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
  2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.
  3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.
  4. Planned cardiovascular revascularization or planned implantation of CRT device.
  5. History of heart transplant or on heart transplant list.
  6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.
  7. Systemic hypotension or uncontrolled systemic hypertension.
  8. History of Pericardial constriction or hypertrophic cardiomyopathy.
  9. History of significant valvular stenosis or regurgitation.
  10. Participants with a pneumonectomy or more than moderate (COPD) or mild interstitial lung disease (ILD) or untreated mild obstructive sleep apnea (OSA).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Investigational Product

    HS235 Subcutaneous Injection

    Biological: HS235

  • Placebo comparator
    Placebo

    Subcutaneous Injection

    Other: Placebo

Interventions

  • BiologicalHS235

    Subcutaneous Injection

  • OtherPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Incidence and Number of Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The incidence and number of participants who experience an AE will be reported.

    Time frame: Up to 85 weeks

07

Study locations

3 of 3 sites recruiting
  • Investigational Site-105
    Kansas City, Missouri 64111, United States
    Recruiting
  • Investigational Site-101
    Greenville, South Carolina 29605, United States
    Recruiting
  • Investigational Site-103
    Dallas, Texas 75390, United States
    Recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 27 months after the start.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 14, 2025
StartActual
Oct 21, 2026was Aug 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Investigational Site-105 · Kansas City, United States
  • Investigational Site-103 · Dallas, United States
across 2 updates, Sep 29, 2026 – Oct 30, 2026
Start date
Aug 2026→Oct 21, 2026 (actual)
moved 2 times, Sep 29, 2026 – Oct 30, 2026
Eligibility
4 inclusion criteria edited, 1 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedmPAP ≥ 25 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
  • EditeddPAP ≥ 15 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
  • AddedHemodynamic evidence of pre-capillary PH based on presence of PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU obtained on most recent RHC obtained prior to screening.
  • EditedHemodynamic evidence of Cpc-PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
  • EditedBody mass index ≥ 3025 to ≤ 50 kg/m2 and Body weight ≤140 kg.
Exclusion criteria
  • EditedParticipants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or untreated mild obstructive sleep apnea (OSA).
Sep 29, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameIncidence and Number of Adverse Events (AEs)Up to 24 weeks → Up to 85 weeks
Sep 29, 2026
Title
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension andDue to Heart Failure With Preserved Ejection Fraction (HFpEF)
Sep 29, 2026
Sponsor
35Pharma Inc→35Pharma Inc., a GSK company
Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    1 site added
    Show site
    • Investigational Site-103 · Dallas, United States
    Start date Sep 2026→Oct 21, 2026 (now actual)
    Sponsor 35Pharma Inc→35Pharma Inc., a GSK company
    + 1 other change: identifiers
  2. Sep 29, 2026
    1 site added
    Show site
    • Investigational Site-105 · Kansas City, United States
    Start date Aug 2026→Sep 2026
    Eligibility 4 inclusion criteria edited, 1 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedmPAP ≥ 25 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
    • EditeddPAP ≥ 15 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
    • AddedHemodynamic evidence of pre-capillary PH based on presence of PVR ≥ 240 dyn*sec/cm5 or ≥ 3 WU obtained on most recent RHC obtained prior to screening.
    • EditedHemodynamic evidence of Cpc-PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
    • EditedBody mass index ≥ 3025 to ≤ 50 kg/m2 and Body weight ≤140 kg.
    Exclusion criteria
    • EditedParticipants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or untreated mild obstructive sleep apnea (OSA).
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameIncidence and Number of Adverse Events (AEs)Up to 24 weeks → Up to 85 weeks
    Title HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension andDue to Heart Failure With Preserved Ejection Fraction (HFpEF)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07123779
Lead sponsor
35Pharma Inc., a GSK company
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Oct 21, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS235

Start the discussion